Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Phase II Study of Ruxolitinib, a Selective JAK1/2 Inhibitor, in Patients With Metastatic Triple-Negative Breast CancerNPJ Breast Cancer 2018 Jul 01;4(xx)10, DG Stover, CR Gil Del Alcazar, J Brock, H Guo, B Overmoyer, J Balko, Q Xu, A Bardia, SM Tolaney, R Gelman, M Lloyd, Y Wang, Y Xu, F Michor, V Wang, EP Winer, K Polyak, NU Lin
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.